A 25-Signal Proteomic Signature and Outcome for Patients With Resected Non-Small-Cell Lung Cancer.
In: JNCI: Journal of the National Cancer Institute, Jg. 99 (2007-06-06), Heft 11, S. 858-867
Online
academicJournal
Zugriff:
Background Among patients with non-small-cell lung cancer (NSCLC), those with poor prognosis cannot be distinguished from those with good prognosis. Methods Matrix-assisted laser desorption-ionization mass spectrometry was used to analyze protein profiles of 174 specimens from NSCLC tumors and 27 specimens from normal lung tissue and to derive a prognosis- associated proteomic signature. Frozen resected tissue specimens were randomly divided into a training set (116 NSCLC and 20 normal lung specimens) and an independent, blinded validation set (58 NSCLC and seven normal lung specimens). Mass spectrometry signals from training set specimens that were differentially associated with specimens from patients with a high risk of recurrence (i.e., who died within 5 years of surgical treatment because of relapse) compared with those from patients with a low risk of recurrence (i.e., alive with no symptoms of relapse after a median follow-up of 89 months) were selected by use of the Fisher's exact test, the Kruskal-Wallis test, and the significance analysis of microarray test. These signals were used to build an individualized, weighted voting-based prognostic signature. The sig- nature was then validated in the independent dataset. Survival was assessed by multivariable Cox regression analysis. Proteins corresponding to individual signals were identified by ion-trap mass spectrometry coupled with high-performance liquid chromatography. All statistical tests were two-sided. Results From 2630 mass spectrometry signals from specimens in the training cohort, we derived a signature of 25 signals that was associated with both relapse-free survival and overall survival. Among stage I NSCLC patients in the validation set, the signature was statistically significantly associated with both overall survival (hazard ratio [HRI of death for patients in the high-risk group compared with those in the low-risk group = 61.1, 95% confidence interval [CI] = 8.9 to 419.2, P<.001) and relapse-free survival (HR of relapse = 11.7, 95% Cl = 3.1 to 44.8, P<.001). Proteins corresponding to signals in the signature were identified that had various cellular functions, including ribosomal protein L26-like 1, acylphosphatase, and phosphoprotein enriched in astrocytes 15. Conclusions We defined a mass spectrometry signature that was associated with survival among NSCLC patients and appeared to distinguish those with poor prognosis from those with good prognosis. [ABSTRACT FROM AUTHOR]
Copyright of JNCI: Journal of the National Cancer Institute is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
A 25-Signal Proteomic Signature and Outcome for Patients With Resected Non-Small-Cell Lung Cancer.
|
---|---|
Autor/in / Beteiligte Person: | Yanagisawa, Kiyoshi ; Tomida, Shuta ; Shimada, Yukako ; Yatabe, Yasushi ; Mitsudomi, Tetsuya ; Takahashi, Takashi |
Link: | |
Zeitschrift: | JNCI: Journal of the National Cancer Institute, Jg. 99 (2007-06-06), Heft 11, S. 858-867 |
Veröffentlichung: | 2007 |
Medientyp: | academicJournal |
ISSN: | 0027-8874 (print) |
DOI: | 10.1093/jnci/djk197 |
Schlagwort: |
|
Sonstiges: |
|